FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051228799> ?p ?o ?g. }

• W2051228799 endingPage "4628" @default.
• W2051228799 startingPage "4613" @default.
• W2051228799 abstract "The human formylpeptide receptor (FPR) is a seven-transmembranous G-protein-coupled receptor (7TM-GPCR) for chemotactic peptides of bacterial origins, possibly involved in the recruitment and activation of neutrophils in various inflammatory diseases of mucosal epithelia. Mutational analyses suggest that interactions of formylated peptides with FPR occur on the outer exoplasmic leaflet/domains of the plasma membrane. The immunosuppressive and antifungal antibiotic cyclic undecapeptide cyclosporin A (CsA; cyclo-[MeBmt(1)-Abu(2)-MeGly(3)-MeLeu(4)-Val(5)-MeLeu(6)-Ala(7)-D-Ala(8)-MeLeu(9)-MeLeu(10)-MeVal(11)]) and some tested analogues such as [Ala(2)]-CsA, [Thr(2)]-CsA, [Val(2)]-CsA, and [Nva(2)]-CsA were able of inhibiting the binding of formylpeptides to the FPR, with [D-MeVal(11)]-CsA (CsH) being much more active than the other analogues. CsH is devoid of immunosuppressive and antifungal activities, and its large potency for human FPR inhibition is of inverse agonism origin. Formylpeptide binding to FPR-expressing cells does not only induce chemotaxis; it also causes a rapid release of granule enzymes in the extracellular medium, allowing the easy monitoring of any inhibition of FPR function in vivo (with intact live cells). With such an assay, CsH was confirmed to be the most potent FPR inhibitory cyclosporin, although a far related immunosuppressive cyclosporin analogue, FR901459 ([Thr(2), Leu(5), Leu(10)]-CsA), was found to display a high FPR inhibitory activity (FPR-InhA). To establish structure-activity relationships (SAR) for FPR function inhibition, 59 cyclosporins were now studied by this standardized assay (with differentiated human leukemic cell line HL-60 as FPR-expressing cells and with N-acetyl-beta-D-glucosaminidase release as read-out). These SAR confirmed the low FPR-InhA of classical cyclosporins, where such activity was only seldom found: the most active ones ([Thr(2), Ile(5)]-CsA, [aMeIle(11)]-CsA, and [MeAla(11)]-CsA) remained 3-10-fold less potent than CsH. In contrast, the SAR disclosed that N(10)-desmethylated cyclosporins were particularly prone to display a large FPR-InhA: their most potent one was a [Thr(2), Gly(3), Leu(5), D-Hiv(8), Leu(10)]-CsA, found to be only 2-4-fold less active than [D-MeVal(11)]-CsA (CsH), with which it shows six differences out of 11 residues. Because the free conformations of both CsH and N(10)-desmethylated cyclosporins differ from those of classical (N(10)-methylated, [L-MeVal(11)]-using) cyclosporins, these potent FPR inhibitory cyclosporins probably bind to FPR pharmacophores for which classical cyclosporins show little affinity. Moreover, because the conformations of the N(10)-desmethylated cyclosporins widely differ from the CsH one, they probably bind to different pharmacophores on the FPR molecules." @default.
• W2051228799 created "2016-06-24" @default.
• W2051228799 creator A5019802504 @default.
• W2051228799 creator A5024972612 @default.
• W2051228799 creator A5039370221 @default.
• W2051228799 creator A5074986241 @default.
• W2051228799 creator A5089379951 @default.
• W2051228799 date "2002-09-12" @default.
• W2051228799 modified "2023-10-13" @default.
• W2051228799 title "Cyclosporins: Structure−Activity Relationships for the Inhibition of the Human <i>FPR1</i> Formylpeptide Receptor" @default.
• W2051228799 cites W1495718547 @default.
• W2051228799 cites W1608128587 @default.
• W2051228799 cites W1920164864 @default.
• W2051228799 cites W1969971113 @default.
• W2051228799 cites W1977986244 @default.
• W2051228799 cites W1985018359 @default.
• W2051228799 cites W1991574245 @default.
• W2051228799 cites W2015554994 @default.
• W2051228799 cites W2025376469 @default.
• W2051228799 cites W2045235316 @default.
• W2051228799 cites W2066068025 @default.
• W2051228799 cites W2073863059 @default.
• W2051228799 cites W2079146411 @default.
• W2051228799 cites W2086722340 @default.
• W2051228799 cites W2111687259 @default.
• W2051228799 cites W2131472380 @default.
• W2051228799 cites W2139169485 @default.
• W2051228799 doi "https://doi.org/10.1021/jm010987v" @default.
• W2051228799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12361388" @default.
• W2051228799 hasPublicationYear "2002" @default.
• W2051228799 type Work @default.
• W2051228799 sameAs 2051228799 @default.
• W2051228799 citedByCount "30" @default.
• W2051228799 countsByYear W20512287992012 @default.
• W2051228799 countsByYear W20512287992013 @default.
• W2051228799 countsByYear W20512287992014 @default.
• W2051228799 countsByYear W20512287992015 @default.
• W2051228799 countsByYear W20512287992016 @default.
• W2051228799 countsByYear W20512287992017 @default.
• W2051228799 countsByYear W20512287992018 @default.
• W2051228799 countsByYear W20512287992019 @default.
• W2051228799 countsByYear W20512287992020 @default.
• W2051228799 countsByYear W20512287992022 @default.
• W2051228799 countsByYear W20512287992023 @default.
• W2051228799 crossrefType "journal-article" @default.
• W2051228799 hasAuthorship W2051228799A5019802504 @default.
• W2051228799 hasAuthorship W2051228799A5024972612 @default.
• W2051228799 hasAuthorship W2051228799A5039370221 @default.
• W2051228799 hasAuthorship W2051228799A5074986241 @default.
• W2051228799 hasAuthorship W2051228799A5089379951 @default.
• W2051228799 hasConcept C116073593 @default.
• W2051228799 hasConcept C126322002 @default.
• W2051228799 hasConcept C13935069 @default.
• W2051228799 hasConcept C150903083 @default.
• W2051228799 hasConcept C170493617 @default.
• W2051228799 hasConcept C185592680 @default.
• W2051228799 hasConcept C202751555 @default.
• W2051228799 hasConcept C207001950 @default.
• W2051228799 hasConcept C2776535732 @default.
• W2051228799 hasConcept C2776731609 @default.
• W2051228799 hasConcept C2779281246 @default.
• W2051228799 hasConcept C2911091166 @default.
• W2051228799 hasConcept C54166955 @default.
• W2051228799 hasConcept C55493867 @default.
• W2051228799 hasConcept C71924100 @default.
• W2051228799 hasConcept C86803240 @default.
• W2051228799 hasConcept C98274493 @default.
• W2051228799 hasConceptScore W2051228799C116073593 @default.
• W2051228799 hasConceptScore W2051228799C126322002 @default.
• W2051228799 hasConceptScore W2051228799C13935069 @default.
• W2051228799 hasConceptScore W2051228799C150903083 @default.
• W2051228799 hasConceptScore W2051228799C170493617 @default.
• W2051228799 hasConceptScore W2051228799C185592680 @default.
• W2051228799 hasConceptScore W2051228799C202751555 @default.
• W2051228799 hasConceptScore W2051228799C207001950 @default.
• W2051228799 hasConceptScore W2051228799C2776535732 @default.
• W2051228799 hasConceptScore W2051228799C2776731609 @default.
• W2051228799 hasConceptScore W2051228799C2779281246 @default.
• W2051228799 hasConceptScore W2051228799C2911091166 @default.
• W2051228799 hasConceptScore W2051228799C54166955 @default.
• W2051228799 hasConceptScore W2051228799C55493867 @default.
• W2051228799 hasConceptScore W2051228799C71924100 @default.
• W2051228799 hasConceptScore W2051228799C86803240 @default.
• W2051228799 hasConceptScore W2051228799C98274493 @default.
• W2051228799 hasIssue "21" @default.
• W2051228799 hasLocation W20512287991 @default.
• W2051228799 hasLocation W20512287992 @default.
• W2051228799 hasOpenAccess W2051228799 @default.
• W2051228799 hasPrimaryLocation W20512287991 @default.
• W2051228799 hasRelatedWork W1980025611 @default.
• W2051228799 hasRelatedWork W1981071014 @default.
• W2051228799 hasRelatedWork W2011828214 @default.
• W2051228799 hasRelatedWork W2015674430 @default.
• W2051228799 hasRelatedWork W2045322776 @default.
• W2051228799 hasRelatedWork W2049656913 @default.
• W2051228799 hasRelatedWork W2051835559 @default.
• W2051228799 hasRelatedWork W2079269249 @default.
• W2051228799 hasRelatedWork W2433311123 @default.

• next